Scholars Central

Case reportPublished 14 Apr 2015

Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report

Authors: Reure J, Follana P, Ferrero JM

Clinical Pharmacology & Biopharmaceutics

Volume 4 · Issue 1 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: HER 2 Metastatic Breast Cancer (MBC) is usually considered incurable. Prognosis has considerably improved over the past two decades with the advent of new therapies such as monoclonal antibodies interfering with the Her2/neu receptor. Case presentation: We present a case of 61 year old woman with Her2 positive MBC without any sign of recurrence 5 years after the end of trastuzumab and who could be potentially considered cured. Conclusion: In case of sustained response, stopping trastuzumab is possible without recurrence. We can reasonably hope that patients without recurrence after 5 years, as in our case, are definitely cured.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Pharmacology & Biopharmaceutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Reure J”
  • BylineArticles whose byline prints “Follana P”
  • BylineArticles whose byline prints “Ferrero JM”